Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

OXB to participate in upcoming investor conferences and events Oxford, UK – 27 October 2025: OXB (LSE: OXB), a global quality ...

The U.S. IND CDMO market offers growth via extensive pipelines in oncology and rare diseases, driven by technological advancements, outsourcing trends, regulatory efficiencies, and modular GMP ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a ...

About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...

The partner firm has used 4basebio's template to develop an mRNA product which has been tested on patients in phase-one and two clinical trials, following investigational new drug approval from the US ...

INOVIO’s DNA medicines platform combines proprietary DNA plasmid design with CELLECTRA delivery technology ... positioning ...

Artificial intelligence (AI) holds promising potential for advancing nuclear energy production. These sophisticated computer systems mimic human logic in problem solving and decision making. With its ...